Preliminary evidence that early reduction in p11 levels in natural killer cells and monocytes predicts the likelihood of antidepressant response to chronic citalopram.

The prediction of treatment response in many neuropsychiatric disorders would be facilitated by easily accessible biomarkers. Using flow cytometry, we herein demonstrate correlations between early reductions of p11 levels in Natural Killer (NK) cells and monocytes and antidepressant response to citalopram in patients with major depressive disorder (MDD).

Treating partial responders to antidepressant treatment.

Many patients with major depressive disorder only partially respond to initial antidepressant treatment. Residual depressive symptoms need to be addressed so that patients can achieve full remission and return to presymptomatic levels of functioning. This case vignette presents Ms M, a 26-year-old woman who continues to experience depression, fatigue, and sleepiness after adequate antidepressant therapy, and discusses pharmacologic strategies to relieve residual symptoms.

Treating depression to full remission.

For more than a decade, the goal of major depressive disorder treatment has been achieving and sustaining remission, which involves complete resolution of depressive symptoms and a return to previous levels of mental and physical functioning. By implementing measurement-based care, clinicians may better assess patient response to treatment. Several depression rating scales are available for use in clinical practice.

Criminal correlates of injury-related emergency department recidivism.

To investigate criminal and high-risk lifestyle factors that predict emergency department (ED) recidivism, a longitudinal (8-year) cohort study of ED trauma patients was conducted. Study patients provided risk and lifestyle behavior information via semi-structured interview. ED revisit and re-injury rates for 1995-2003 were acquired through hospital record review.

Treating depression complicated by comorbid medical illness or anxiety.

In this online activity, Trivedi discusses pharmacotherapy treatments for depression in the presence of comorbid medical illness or physical symptoms. The focus is on key aspects of treatment such as remission as the treatment goal, effects of different classes of antidepressants, and benefits of using treatment algorithms. Clayton addresses issues related to comorbid depression and anxiety including prevalence and recognition, risk factors and outcomes, and treatment considerations.

Exercise as an augmentation strategy for treatment of major depression.

The use of augmentation strategies among patients with major depression is increasing because rates of complete remission with standard antidepressant monotherapy are quite low. Clinical and neurobiological data suggest that exercise may be a good candidate for use as an augmentation treatment for depression. This pilot study examined the use of exercise to augment antidepressant medication in patients with major depression.

Inverse association between physical inactivity and mental health in men and women.

Purpose: The Aerobics Center Longitudinal Study (ACLS) provides the opportunity to evaluate associations between measures of physical activity and mental health in a large and well-characterized population of men and women.

Methods: Participants were 5451 men and 1277 women (20-88 yr) who completed a maximal fitness treadmill test and self-report measures of habitual physical activity, depressive symptoms (Center for Epidemiological Studies Scale for Depression; CES-D) and emotional well-being (General Well-Being Schedule; GWB). To evaluate the dose-response gradient of the association, we classified the sample, separately for men and women, into three levels of relative cardiorespiratory (CR) fitness (low, moderate, high) on the maximal treadmill test, and four levels on a physical activity index of weekly walking, jogging, and running.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Context: Paroxetine controlled release (CR) is approved for the treatment of major depressive disorder (MDD) in the dosage range of 25 to 62.5 mg daily. However, lower daily doses (12.